Carlos M. De Castro, MD, highlights the phase III Apply-PNH study presented at ASH 2022.
ASH 2022 Post Conference Perspectives: Innovations in Paroxysmal Nocturnal Hemoglobinuria (PNH)
Dr De Castro provides an overview of IV versus oral therapies for patients with PNH.
Biosimilar products may be utilized as treatment options in PNH.
Dr De Castro explores considerations surrounding cost in treatment of PNH.
In his closing thoughts, Dr De Castro provides a final overview of the ASH conference, highlighting updates in PNH treatment.
Advertisement
Advertisement
Trending on AJMC
1
Sudden Death in HFpEF Often Preceded by Clinical Decline
2
How Often Do Health Insurers Deny Doctor-Recommended Care?
3
FDA Issues Complete Response Letter for Cingulate's Once-Daily ADHD Drug CTx-1301
4
New Data Support Pimicotinib as Durable for Rare Tenosynovial Giant Cell Tumor
5